Emerging Therapies for Systolic Heart Failure and Pulmonary Hypertension

Banner: Emerging Therapies for Systolic Heart Failure and Pulmonary Hypertension

Click Here to Watch the Webinar »

Faculty

Warren Rosenblum, M.D.
Assistant Professor of Medicine at the Columbia University Medical Center

Jennifer Haythe, M.D.
Assistant Professor of Medicine at the Columbia University Medical Center

Mathew Maurer, M.D.
Professor of Medicine at the Columbia University Medical Center

Program Description

Emerging Therapies for Systolic Heart Failure and Pulmonary Hypertension is a non-CME webinar discussion, which will focus on education leading to improved patient care and better outcomes.

Target Audience

This activity is designed for primary care physicians, clinical cardiologists, pulmonologist, heart failure physicians and allied health professions caring for this population.

Educational Needs Assessment

Systolic heart failure or heart failure with a reduced ejection fraction is associated with significant morbidity and mortality. While standard therapy for systolic heart failure has been shown to reduce adverse outcomes in this population, patients remain at high risk for functional decline, hospitalization and death. Several new treatment options that modulate heart rate and the natriuretic system have recently been approved for use based on large-scale clinical trials that have demonstrated significant efficacy of these therapies.

Pulmonary hypertension is a disorder characterized by elevated pulmonary artery pressure that has heterogeneous causes. Defining the etiology is essential to the institution of appropriate medical and surgical therapy. There is an ever-enlarging list of targeted therapies for patients with pre-capillary pulmonary hypertension, which have been shown to improve outcomes in affected patients.

This program will explore the current standard of care for management of patients with systolic heart failure and pulmonary hypertension as well as examine the new treatment options that have recently been approved for use.

Learning Objectives

At the end of this program, the attendees will be able to:

  • Delineate the natural history of systolic heart failure and pulmonary hypertension.
  • Describe the appropriate work-up of patients with pulmonary hypertension.
  • Identify the different treatment options for systolic heart failure and pulmonary hypertension and their efficacy.
  • Understand the role of novel, recently approved therapies for these conditions.